Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors
Abstract Background First-line ICI-based therapies are commonplace in mRCC and frequency of irAEs is high. Although prognostication based on irAEs has been demonstrated, prediction of irAE occurrence in mRCC remains a challenge. Early identification of high-risk patients would enable personalized monitoring, earlier detection of irAEs, and more proactive toxicity management. We investigated the role of baseline blood cell count ratios to predict grade ≥2 irAEs with first-line ICI-based therapies in mRCC. Patients and Methods We used the City of Hope national database to retrospectively identify mRCC patients treated with first-line ICI-based therapies from September 2015 to September 2025. Baseline patient demographics and first-line ICI-based regimen were collected. We stratified baseline blood cell ratios: neutrophil-to-eosinophil ratio (NER), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII) using recursive partitioning and evaluated their association with occurrence of grade ≥2 irAEs. Results A total of 198 patients with mRCC were treated with first-line ICI-based therapy, of which 5 were excluded due to insufficient data. Of the 193 evaluable patients, the median age was 64, 100 patients (51.8%) received ICI-ICI and 93 patients (48.2%) received ICI-TKI. Grade ≥2 irAEs were observed in 57 patients (29.5%) and the most common was ALT/AST elevations in 18 patients (9.3%). All baseline blood cell ratios predicted occurrence of grade ≥2 irAEs in separate multivariable logistic regression analyses for each marker, with SII and PLR emerging as subgroup-specific risk factors in the ICI-ICI and ICI-TKI cohorts, respectively. Conclusion Our findings support a novel role for these baseline blood cell ratios as factors associated with grade ≥2 irAEs in mRCC. These findings are hypothesis-generating and warrant prospective validation in larger patient populations.
Authors
- Miguel Zugman (ORCID: https://orcid.org/0000-0002-2181-8405)
- Tanya Dorff
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Yu Jun Li
- Regina Barragán-Carrillo (ORCID: https://orcid.org/0000-0002-3114-0642)
- Daniela V. Castro (ORCID: https://orcid.org/0000-0002-5423-9821)
- Hedyeh Ebrahimi (ORCID: https://orcid.org/0000-0003-3647-7356)
- Nazlı Dizman (ORCID: https://orcid.org/0000-0002-3907-8513)
- Salvador Jaime‐Casas (ORCID: https://orcid.org/0009-0009-4334-1300)
- Koral U. Shah (ORCID: https://orcid.org/0000-0002-4868-8276)
- Kaela Makins (ORCID: https://orcid.org/0009-0002-9934-0832)
- Jadon Cooper Fann (ORCID: https://orcid.org/0009-0002-6194-6660)
- George Zhang (ORCID: https://orcid.org/0009-0005-6646-7644)
- Rahul Winayak
- Ali Moradi (ORCID: https://orcid.org/0000-0001-7316-6122)
- Joann Hsu
- Benjamin Mercier
- Vitor Abreu De Goes
- Alexander Chehrazi-Raffle
- Xiaochen Li
- Nicholas J Salgia
- Abhishek Tripathi
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- City of Hope (US)
- Instituto Nacional de Cancerología (MX)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1093/oncolo/oyag454
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00